Mn Services Vermogensbeheer B.V. Sells 5,400 Shares of Solventum Corporation (NYSE:SOLV)

Mn Services Vermogensbeheer B.V. trimmed its stake in Solventum Corporation (NYSE:SOLV - Free Report) by 9.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,032 shares of the company's stock after selling 5,400 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Solventum were worth $3,728,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of SOLV. Clarity Asset Management Inc. purchased a new position in shares of Solventum in the fourth quarter worth about $25,000. Raiffeisen Bank International AG purchased a new position in Solventum in the 4th quarter valued at approximately $29,000. Colonial Trust Co SC raised its holdings in Solventum by 240.7% during the 4th quarter. Colonial Trust Co SC now owns 511 shares of the company's stock valued at $34,000 after acquiring an additional 361 shares during the period. Banque Transatlantique SA bought a new stake in Solventum during the 4th quarter valued at $42,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Solventum by 48.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 687 shares of the company's stock worth $45,000 after acquiring an additional 223 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on SOLV shares. Piper Sandler upgraded Solventum from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $78.00 to $87.00 in a research note on Monday, May 19th. Mizuho upped their price target on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research report on Monday, March 3rd. Morgan Stanley increased their price target on shares of Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a report on Wednesday, March 5th. Bank of America raised their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Wednesday, February 26th. Finally, The Goldman Sachs Group upped their target price on shares of Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, Solventum currently has an average rating of "Hold" and a consensus target price of $80.29.

Solventum Price Performance

SOLV traded down $0.23 on Wednesday, reaching $72.53. The company had a trading volume of 683,788 shares, compared to its average volume of 1,191,970. Solventum Corporation has a 52-week low of $47.16 and a 52-week high of $85.92. The company has a market cap of $12.55 billion, a price-to-earnings ratio of 33.58, a P/E/G ratio of 1.91 and a beta of 0.54. The company has a debt-to-equity ratio of 2.40, a quick ratio of 0.85 and a current ratio of 1.19. The business has a 50 day simple moving average of $70.29 and a 200 day simple moving average of $71.67.

Solventum (NYSE:SOLV - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.15. Solventum had a net margin of 4.55% and a return on equity of 31.01%. The firm had revenue of $2.07 billion for the quarter, compared to analysts' expectations of $2.02 billion. During the same quarter last year, the company posted $2.08 EPS. The business's quarterly revenue was up 2.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.